Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

ARS Pharmaceuticals (SPRY) EBITDA (2021 - 2025)

ARS Pharmaceuticals (SPRY) has disclosed EBITDA for 5 consecutive years, with -$41.2 million as the latest value for Q4 2025.

  • Quarterly EBITDA fell 182.69% to -$41.2 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$171.4 million through Dec 2025, down 2198.09% year-over-year, with the annual reading at -$171.4 million for FY2025, 2198.09% down from the prior year.
  • EBITDA hit -$41.2 million in Q4 2025 for ARS Pharmaceuticals, up from -$51.1 million in the prior quarter.
  • In the past five years, EBITDA ranged from a high of $49.8 million in Q4 2024 to a low of -$51.1 million in Q3 2025.
  • Historically, EBITDA has averaged -$13.6 million across 5 years, with a median of -$15.1 million in 2023.
  • Biggest five-year swings in EBITDA: surged 815.94% in 2024 and later tumbled 258.95% in 2025.
  • Year by year, EBITDA stood at $45.8 million in 2021, then crashed by 130.61% to -$14.0 million in 2022, then surged by 50.38% to -$7.0 million in 2023, then soared by 815.94% to $49.8 million in 2024, then plummeted by 182.69% to -$41.2 million in 2025.
  • Business Quant data shows EBITDA for SPRY at -$41.2 million in Q4 2025, -$51.1 million in Q3 2025, and -$45.0 million in Q2 2025.